Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Trial

Inclusion Criteria:

   - children between 3 years and 12 years 11 months

   - diagnosis of autism spectrum disorder confirmed with the Autism Diagnostic Interview-
   Revised and the Autism Diagnostic Observation Schedule-2, Brief Observation of
   Symptoms of Autism, or Childhood Autism Rating Scale

   - at least moderate severity of restricted and repetitive behaviors defined by a
   Children's Yale-Brown Obsessive Compulsive Scale for Autism Spectrum Disorder score ≥
   11

   - physical development indicative of prepubescence as defined by criteria for Tanner
   Stage 1

   - passes MR safety screening (e.g., no metal in the body) and attempts baseline
   neuroimaging (MRI or EEG)

   - have stable medication regimens (≥ 30 days) and psychosocial treatments (≥ 60 days)
   prior to randomization with no anticipated changes during the trial

Exclusion Criteria:

   - presence of known genetic abnormalities associated with ASD (e.g. Fragile X)

   - current or life-time diagnosis of severe psychiatric disorder (e.g., schizophrenia)

   - presence of significant medical problems

   - the inability of at least one caregiver to speak and read English to a sufficient
   level

   - participants taking glutathione agents/prodrugs

   - history of any adverse effects to glutathione agents/prodrugs

   - the inability to drink a sample study compound dissolved in liquid